Mylan Speciality Lp patents expiration
1. Astepro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(2 years from now) | |
| US9919050 | MYLAN SPECIALITY LP | Compositions comprising azelastine |
Nov, 2025
(2 years from now) | |
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
2. Dymista patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(3 months ago) | |
| US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(3 months ago) | |
| US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(30 days ago) | |
|
US9259428 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Dec, 2023
(2 months from now) | |
|
US8163723 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(5 months from now) | |
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(2 years from now) | |
|
US8168620 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2026
(2 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis; Treatment of allergic rhinitis, including seasonal allergic rhinitis; Allergic rhinitis; Treatment of symptoms of seasonal allergic rhinitis; Relief of symptom...
Dosage: SPRAY, METERED;NASAL
DYMISTA family patents
3. Edluar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597281 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Apr, 2027
(3 years from now) | |
| US9265720 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Feb, 2031
(7 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;SUBLINGUAL
EDLUAR family patents
4. Elestrin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7198801 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Jun, 2022
(1 year, 3 months ago) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
ELESTRIN family patents
5. Epi E Z Pen Jr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 11 months from now) | |
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 11 months from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(1 year, 11 months from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 11 months from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 11 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 22 December, 1987
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
EPI E Z PEN JR family patents
6. Rowasa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(3 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
ROWASA family patents
7. Tobi Podhaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421166 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(9 months ago) | |
| US7368102 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycosides |
Dec, 2022
(9 months ago) | |
| US8715623 | MYLAN SPECIALITY LP | Pulmonary delivery of aminoglycoside |
Dec, 2022
(9 months ago) | |
| US7516741 | MYLAN SPECIALITY LP | Aerosolization apparatus with feedback mechanism |
Jan, 2024
(3 months from now) | |
| USRE47526 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Apr, 2024
(6 months from now) | |
| US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(11 months from now) | |
| US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(1 year, 1 month from now) | |
| US8664187 | MYLAN SPECIALITY LP | Methods of treatment of endobronchial infections |
Jun, 2025
(1 year, 8 months from now) | |
| US7559325 | MYLAN SPECIALITY LP | Aerosolization apparatus with air inlet shield |
Oct, 2025
(2 years from now) | |
| US8869794 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncturing member |
Sep, 2028
(4 years from now) | |
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(7 years from now) | |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic